Novan’s Stock Surges As SB206 Can Potentially Shorten Duration Of Contagious Skin Disease
Novan Inc (NASDAQ:NOVN) has announced positive topline efficacy and safety results from the B-SIMPLE4 Phase 3 trial evaluating SB206, a topical…
Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes
Precigen Inc’s (NASDAQ:PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type…
Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease Candidate; Stock Tumbles
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the Phase 2 data evaluating VX-864 in alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype.
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm.
BofA Downgrades Clover Health After 100% Stock Surge
Clover Health Investments Corp.’s (NASDAQ: CLOV) stock has spiked by around 100% over the past week and is now at a 70% premium to its closest competitor, Alignment Healthcare Inc (NASDAQ: ALHC), according to BofA
HAVN Life is Looking for a Safe Haven to Mental Health Through Psychedelic Medicine
Most companies' success stories come as a result of wanting to accomplish a greater purpose. For HAVN Life Sciences Inc. (CSE: HAVN) (OTC PINK: HAVLF) (FSE: 5NP) CEO Tim Moore, his personal experience took him to explore alternatives beyond traditional pharma.
‘No Obamacare ruling today. The court issued one opinions relating to the Armed Career Criminal Act’ -Tweet From Bloomberg Law Reporter
https://twitter.com/WheelerLydia/status/1402989730522755085
Amgen’s Stomach Cancer Drug Acquired in Five Prime Buyout Extends Patients’ Lives, Mid-Stage Study Shows
Amgen Inc (NASDAQ:AMGN) has announced updated results for investigational bemarituzumab combined with chemotherapy from the Phase 2 FIGHT trial in patients…
Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise
Cyclerion Therapeutics Inc (NASDAQ:CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ:AKBA) for the development and commercialization of…